TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 18, 2025--

Positive results from the DESTINY-Breast05 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and a high risk of disease recurrence. Results were presented today ( LBA1 ) alongside the results of DESTINY-Breast11 ( 291O ) in Presidential Symposium I at the 2025 European Society for Medical Oncology (#ESMO25) Congress.